Summary sheet
The project concerns the Promoter's corporate research and development (R&D) programme in its medical division for the period 2021-2023, with a particular focus on connected health devices.
The project's emphasis on connected health devices follows the trend of therapy automation in hospitals through diagnostic and therapeutic assistance systems. Since the outbreak of COVID-19, the relevance and demand for connected health devices has significantly increased.
The project concerns investments in research and development that are expected to be carried out in existing facilities, already authorised, and which would therefore not require an environmental impact assessment (EIA) 2014/52/EU amending the EIA Directive 2011/92/EC. Full environmental details will be verified during the appraisal.
The Promoter is a private company not operating in the utilities sector, and is thus not covered by EU directives on procurement.